Spyre Therapeutics (NASDAQ: SYRE) announced inducement equity awards: stock options to purchase an aggregate of 42,000 shares granted to six non-executive employees under the 2018 Equity Inducement Plan. The grants were approved on January 2, 2026 and were described as material to each employee's acceptance of employment in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have a 10-year term, an exercise price of $30.58 (Spyre closing price on January 2, 2026), and vest one-fourth on the first anniversary of each employee’s start date with the remainder vesting monthly at 1/48th thereafter, subject to continuous service and the terms of the 2018 Plan.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – SYRE
+1.56%
+1.56%Session close to close
In the Jan 9 session, SYRE gained 1.56%, reflecting a mild positive market reaction.
This announcement details standard equity inducement grants—42,000 stock options with a $30.58 exerc...
Analysis
This announcement details standard equity inducement grants—42,000 stock options with a $30.58 exercise price and a 10-year term—used to attract non-executive talent under the 2018 plan. Vesting follows a one-year cliff and then 1/48th monthly, tying employees to long-term performance. In context of recent financings, clinical progress, and prior inducement awards, investors may track overall equity compensation levels and dilution over time rather than viewing this as a standalone catalyst.
Key Figures
Inducement options:42,000 sharesGrant approval date:January 2, 2026Option term:10 years+5 more
8 metrics
Inducement options42,000 sharesStock options granted to six non-executive employees under 2018 Plan
Announcement of participation in three November healthcare investor conferences.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Positive R&D and financing news previously saw muted or negative next-day moves, while routine items like conferences and inducement grants showed mixed, generally modest reactions.
Recent Company History
Over the last few months, Spyre reported multiple developments, including equity inducement grants on Nov 7 and Dec 5, 2025, an underwritten offering and cash build highlighted in October filings, and notable clinical and financial updates on Nov 4, 2025 with positive Phase 1 data for SPY003 and Q3 results. Those more material updates coincided with small negative price reactions, while conference participation and prior inducement grants produced modest positive or mixed moves, framing today’s HR-related option awards within a pattern of limited trading impact.
"approved the grant of stock options to purchase an aggregate of 42,000 shares"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
equity inducement awardsfinancial
"shares of common stock of Spyre to six non-executive employees as equity inducement awards"
Equity inducement awards are special stock-based rewards given to new employees to encourage them to join a company or stay long-term. They are like signing bonuses paid with company shares instead of cash, helping motivate employees to contribute to the company's success.
exercise pricefinancial
"a 10-year term and an exercise price equal to $30.58, the closing price per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Nasdaq Listing Rule 5635(c)(4)regulatory
"material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
WALTHAM, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease and rheumatic diseases, today announced that Spyre’s independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 42,000 shares of common stock of Spyre to six non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the “2018 Plan”). The stock options were approved on January 2, 2026 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options were granted with a 10-year term and an exercise price equal to $30.58, the closing price per share of Spyre's common stock as reported by Nasdaq on January 2, 2026. The options granted to the employees shall vest and become exercisable as to one-fourth (1/4th) of the shares subject to the respective options on the first anniversary of the employee’s start date, and one-forty-eighth (1/48th) of the shares subject to the respective options shall vest and become exercisable monthly thereafter, in each case, subject to continuous service with Spyre through the applicable vesting dates. The stock options are subject to the terms of the 2018 Plan.
About Spyre Therapeutics
Spyre Therapeutics is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.
For more information, please visit http://spyre.com.
For Investors: Eric McIntyre SVP of Finance and Investor Relations Spyre Therapeutics Eric.mcintyre@spyre.com
FAQ
How many shares did Spyre Therapeutics (SYRE) grant in the January 8, 2026 inducement awards?
Spyre granted stock options to purchase an aggregate of 42,000 shares to six non-executive employees.
What was the exercise price and term for the SYRE inducement stock options approved January 2, 2026?
The options have a 10-year term and an exercise price of $30.58, the closing price on January 2, 2026.
What is the vesting schedule for the SYRE inducement options?
Options vest 25% on the first anniversary of each employee’s start date and then 1/48th monthly thereafter, subject to continuous service.
Who received the SYRE inducement awards announced January 8, 2026?
The awards were granted to six non-executive employees as equity inducement awards under the 2018 Plan.
Why did Spyre reference Nasdaq Listing Rule 5635(c)(4) for the January 2026 grants?
The company said the stock options were material to each employee's acceptance of employment and thus were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Are the SYRE inducement options subject to additional plan terms or service conditions?
Yes; the options are subject to the terms of the 2018 Plan and vesting is conditioned on continuous service through applicable vesting dates.
